Surrozen (SRZN) EPS (Basic) (2020 - 2026)
Surrozen (SRZN) recorded quarterly EPS (Basic) of -$11.65 in Q1 2026, up 51.21% quarter-over-quarter from -$23.88 in Q4 2025, and down 56.8% on a YoY basis from -$26.97 in Q1 2025.
Surrozen (SRZN) EPS (Basic) (2020 - 2026) Analysis & Trends
Surrozen's EPS (Basic) history runs 7 years deep, the most recent figure standing at -$11.65 for Q1 2026.
- In Q1 2026, EPS (Basic) fell 56.8% year-over-year to -$11.65; the TTM figure through Mar 2026 stood at -$41.34 (down 65.62% YoY), while the FY2025 annual figure was -$32.37, down 49.38% from the prior year.
- EPS (Basic) was -$11.65 for Q1 2026 at Surrozen, up from -$23.88 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $2.55 in Q2 2025 to a low of -$732.5 in Q4 2022.
- Historically, EPS (Basic) has averaged -$48.55 across 5 years, with a median of -$5.14 in 2023.
- The sharpest annual moves came in 2023 and 2025: EPS (Basic) tumbled 3013.04% in 2023, then jumped 131.91% in 2025.
- A 5-year view of EPS (Basic) shows it stood at -$732.5 in 2022, then surged by 99.4% to -$4.37 in 2023, then sank by 108.24% to -$9.1 in 2024, then tumbled by 162.42% to -$23.88 in 2025, then jumped by 51.21% to -$11.65 in 2026.
- The last three EPS (Basic) figures came in at -$11.65 (Q1 2026), -$23.88 (Q4 2025), and -$8.36 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.06 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.06 |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -11.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.65 |
| Dec 31, 2025 | -23.88 |
| Sep 30, 2025 | -8.36 |
| Jun 30, 2025 | 2.55 |
| Mar 31, 2025 | -7.43 |
| Dec 31, 2024 | -9.10 |
| Sep 30, 2024 | -0.44 |
| Jun 30, 2024 | -7.99 |
| Mar 31, 2024 | -4.24 |
| Dec 31, 2023 | -4.37 |
| Sep 30, 2023 | -5.14 |
| Jun 30, 2023 | -4.68 |
| Mar 31, 2023 | -7.16 |
| Dec 31, 2022 | -732.50 |
| Sep 30, 2022 | -0.38 |
| Jun 30, 2022 | -0.40 |
| Mar 31, 2022 | -0.23 |
| Dec 31, 2021 | -605.65 |
| Sep 30, 2021 | -0.51 |
| Jun 30, 2021 | -0.69 |